Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Oxybutynin 10% for Primary Focal Hyperhidrosis
NCT02973659Completed
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- May 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of oxybutynin in primary focal hyperhidrosis (PFH) (3 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Dermatology Life Quality Index at 30 days and Hyperhidrosis Disease Severity Scale at 30 days. Started May 2015; status: completed.
02
Drugs
oxybutynin
03
Conditions
primary focal hyperhidrosis (PFH)
Beyond the preview
Go deeper on NCT02973659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973659.